- Home
- PETS vs HOOK Comparison
PETS vs HOOK Comparison
Compare PETS & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- HOOK
- Stock Information
- Founded
- PETS 1996
- HOOK 2011
- Country
- PETS United States
- HOOK United States
- Employees
- PETS N/A
- HOOK N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- HOOK Health Care
- Exchange
- PETS Nasdaq
- HOOK Nasdaq
- Market Cap
- PETS 62.8M
- HOOK 9.3M
- IPO Year
- PETS N/A
- HOOK 2019
- Fundamental
- Price
- PETS $3.40
- HOOK $1.21
- Analyst Decision
- PETS Sell
- HOOK Buy
- Analyst Count
- PETS 2
- HOOK 4
- Target Price
- PETS $3.35
- HOOK $10.67
- AVG Volume (30 Days)
- PETS 141.6K
- HOOK 65.6K
- Earning Date
- PETS 08-05-2025
- HOOK 08-07-2025
- Dividend Yield
- PETS N/A
- HOOK N/A
- EPS Growth
- PETS N/A
- HOOK N/A
- EPS
- PETS 0.02
- HOOK N/A
- Revenue
- PETS $247,010,000.00
- HOOK $9,351,000.00
- Revenue This Year
- PETS N/A
- HOOK N/A
- Revenue Next Year
- PETS N/A
- HOOK N/A
- P/E Ratio
- PETS $192.80
- HOOK N/A
- Revenue Growth
- PETS N/A
- HOOK N/A
- 52 Week Low
- PETS $2.90
- HOOK $0.72
- 52 Week High
- PETS $6.85
- HOOK $6.77
- Technical
- Relative Strength Index (RSI)
- PETS 39.83
- HOOK 37.62
- Support Level
- PETS $3.13
- HOOK $1.17
- Resistance Level
- PETS $3.44
- HOOK $1.35
- Average True Range (ATR)
- PETS 0.18
- HOOK 0.07
- MACD
- PETS -0.02
- HOOK -0.02
- Stochastic Oscillator
- PETS 29.63
- HOOK 15.75
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.